Best Clean Energy Stocks For 2018

What happened

Shares ofBunge Ltd.(NYSE:BG)rose 10% on Wednesday after the agribusiness and food company released strong fourth-quarter 2016 results.

So what

Quarterly revenue grew 8.6% year over year, to $12.1 billion, and translated to 14.1% growth in adjusted earnings per share, to $1.70. Analysts, on average, were only expecting Bunge to report revenue of $11.4 billion and adjusted earnings of $1.57 per share.

IMAGE SOURCE: Bunge Ltd.

Bunge CEO Soren Schroder elaborated:

Bungehad a solid fourth quarter to end a challenging year. Higher Food & Ingredients and Sugar & Bioenergy results in 2016 reflect our team’s hard work to drive structural improvements to increase the underlying competitiveness of our businesses. Agribusiness faced a very competitive global market environment, but finished strong.

Best Clean Energy Stocks For 2018: ServiceMaster Global Holdings, Inc.(SERV)

Advisors’ Opinion:

  • [By Lee Jackson]

    ServiceMaster Global Holdings Inc. (NYSE: SERV) had its top executive selling shares last week. CEO Robert Gillette sold a total of 343,750 shares at prices that ranged from $36.00 to $36.86 apiece. The total for the sale was about$13 million.The company provides residential and commercial services in the United States, and its shares traded onFriday at $35.50.

Best Clean Energy Stocks For 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Alexion Pharmaceuticals (ALXN), a drug maker focused on rare diseases, ended Thursday at the top of the list of the best performing stocks in the S&P 500 index.

    The shares climbed almost 3.3%, or $3.78, to close at $118.35, compared to the S&P 500, which fell almost 16 points, or 0.7% to end at 2,328.95.

    Its been a rough two years for Alexion. Since mid-2015, when the stock traded above $200, shares have tumbled on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of two top executives amid an investigation into sales practices.

    The shares are down more than 3% since the start of 2017.

    Solaris sales will be a focus next week when Alexion reports first quarter financial results. Earlier today, Barclays reiterated an overweight rating on the stock and a $115 price target, but raised its 2018 and 2019 earnings estimates, arguing that rivals are unlikely to significantly challenge either Solaris or the experimental drug ALXN1210.

    …we are increasingly comfortable with the Soliris outlook and now forecast 2021E sales at $4.8B vs. our previous $4.6B, which is +5% ahead of consensus. Weve raised 2017 and 2018 adjusted EPS estimates by $0.05 and $0.10 respectively. Our 5-year revenue CAGR increases by +70 bps to 14.7% while EPS growth has improved by +100 bps to 20.0%, near the top of the peer group.

    Barrons weighed in on Alexion in February, which has been bandied about as a takeout candidate. We have argues

    Earlier this week, Credit Suisse analysts listed Alexion as one of three biotech stocks that will steal the spotlight during earnings season.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) sunk to the bottom of the S&P 500 today, a drop that is being attributed to revelations on Wednesday night that it had to delay its 10-Q because of a whistle blower investigation into its sales practices.

    Getty Images

    Shares of Alexion Pharmaceuticals tumbled 10% to $$113.62 today, while the S&P 500 dipped 0.1% to 2,164.45.

    After speaking with Alexion CEO Vika Sinha, Citigroup’s Robyn Karnauskas and Mohit Bansal see a buying opportunity. “As we highlighted in our previous note, we cannot envision anything that changes numbers fundamentally and see this weakness as buying opportunity,” they write. They also write that they looked at the companies past financials and saw no red flags, while noting that Soliris, the drug that is causing all the problems, “is sold on named patient basis, therefore, chances of fake sales are very minimal.”

    Alexion Pharmaceuticals market capitalization fell to $25.4 billion today from $28.5 billion yesterday.

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Chris Lange]

    Alexion Pharmaceuticals Inc.s (NASDAQ: ALXN) short interest decreased to 4.33 million, compared to the previous level of 4.98 million. Shares closed most recently at $118.83, in a 52-week range of $110.56 to $193.45.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

Best Clean Energy Stocks For 2018: Intuitive Surgical Inc.(ISRG)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, IBM (NYSE:IBM) and Intuitive Surgical (NASDAQ:ISRG) attracted heavy investor interest following their quarterly earnings releases.

  • [By Joseph Hogue]

    Enter Intuitive Surgical (Nasdaq: ISRG) and Da Vinci, a robotic arm that allows surgeons to operate with just a single incision less than an inch in size.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Intuitive Surgical, Inc. (NASDAQ: ISRG) which traded down over 6% at $369.95. The stocks 52-week range is $203.57 to $405.05. Volume was1.9 million versus the daily average of about half a million shares.

  • [By Benzinga News Desk]

    Microsoft (NASDAQ: MSFT) Reports Q4 EPS $0.69 vs. Est. $0.58, Rev. $22.64B vs. Est. $22.14B
    Intuitive Surgical (NASDAQ: ISRG) Reports Q2 GAAP EPS $4.71, Adj. EPS $5.62 vs $4.97 Est., Sales $670.1M vs $540.7M Est.
    Halliburton (NYSE: HAL) Q2 EPS ($0.14) vs ($0.19) est, Revenue $3.84B vs $3.75B est
    Morgan Stanley (NYSE: MS) Q2 EPS $0.75 vs $0.59 est, Revenue $8.9B vs $8.3B est

Leave a Reply

Your email address will not be published. Required fields are marked *